Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$123.74
pos +0.23
+0.19%
Today's Range: 123.40 - 124.31 | JNJ Avg Daily Volume: 6,809,100
Last Update: 04/27/17 - 4:02 PM EDT
Volume: 4,225,152
YTD Performance: 7.20%
Open: $123.58
Previous Close: $123.51
52 Week Range: $109.32 - $129.00
Oustanding Shares: 2,710,891,992
Market Cap: 334,605,398,573
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 2 2 2 2
Hold 10 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 1
Mean Rec. 2.22 2.22 2.37 2.37
Latest Dividend: 0.80
Latest Dividend Yield: 2.59%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 20.10
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
20.10 20.70 30.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.43% 9.39% 23.77%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.60 0.00 0.00
Net Income 7.30 0.20 0.06
EPS 8.20 0.20 0.07
Earnings for JNJ:
EBITDA 24.92B
Revenue 71.89B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.79 $1.77 $7.09 $7.71
Number of Analysts 9 8 12 11
High Estimate $1.86 $1.83 $7.14 $7.86
Low Estimate $1.68 $1.72 $7.00 $7.53
Prior Year $1.74 $1.68 $6.73 $7.09
Growth Rate (Year over Year) 2.87% 5.43% 5.41% 8.67%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Let's pull the band aid off the charts, carefully.
Biotech investors should keep a close eye on the progress in this huge potential market.
Financial names populate the bullish side.
It is a very muddled market, and that demands that we stay patient and wait for greater clarity to develop.
I spent a lot of time on the (respectful) Rosenberg/Kass debate on economic growth and interest rates today:   * And Now A Word From…
As markets yo-yo, both bulls and bears are left seeking leadership.
Despite a long list of negatives, the ursine class has been unable to push the market into a full-blown downtrend.
Bulls are standing in the way of a needed correction.

Feeling The Market's Pain Real Money Pro($)

" It is always by way of pain one arrives at pleasure." - Marquis de Sade   Today's Dow Jones decline is the worst s…
I'm keeping an eye out, but there isn't enough support to suggest that now is the time to start buying.

Columnist Conversations

join me today for a free webinar, we'll be talking about the markets, interest rates and the Fed.  after ...
we have a big winner here, we'll roll it up SOLD XLNX MAY 55 CALL AT 9.55 (in at 5.70) BOUGHT XLNX JUN 6...
View Chart »  View in New Window » XLY has met multiple upside targets, you may want to trail ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.